^
    Back
    Association details:
    Biomarker:BRAF G466V + KIT K509Q
    Cancer:Non Small Cell Lung Cancer
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ESMO 2020
    Title:

    1968p - The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib

    Published date:
    09/14/2020
    Excerpt:
    The patient that had a concurrent BRAF p.(G466V) and KIT p.(K509Q) mutations had a stable disease for only 3 months